Antibiotics: Longer treatment times that benefit children may cost society

Sep 08, 2010

The likelihood that the treatment of a middle ear infection will fail is slightly higher for a child who is given a shorter course of antibiotics, according to a new Cochrane Systematic Review. The results are conclusive, but the researchers say there are other factors that must be considered when the drugs are prescribed.

Most suffer at some point from a middle ear infection, also called acute otitis media (AOM). It is one of the most common reasons for children being prescribed antibiotics, at a cost of up to $5 billion each year in the US alone. Health practitioners vary in the length of course that they prescribe to treat the infection. The standard course in Britain is five days, whereas in North America it is ten. Due to concern about caused by overuse, and the increasing cost of providing these drugs, the researchers decided to update a previous Cochrane Review carried out in 2000.

The updated review included 49 trials involving 12,045 children aged one month to 18 years, 22 of which were studies that had not been included in the original review. According to results, the likelihood of treatment failure with long course antibiotics was one in six compared to one in five with short course antibiotics. Long course was defined as more than one week, whereas short course was defined as less than one week. The researchers concluded that the policy of treating for five days might slightly increase the risk of a child experiencing further symptoms, or a relapse, in the second to third week after starting treatment.

According to the researchers, their work has not changed the findings of the original review and further updates should not be needed. "Any new studies would not change the current outcomes," said lead researcher Terry Klassen, Director of Research, Manitoba Institute of Child Health, the research division of the Children's Hospital Foundation of Manitoba.

"However, it is up to clinicians to assess whether it is worth exposing children to a longer course for the sake of a slightly reduced risk of failure in the short term," said Klassen. "Shorter courses can be safely used and generally produce fewer side effects. It is more difficult to support longer term use of antibiotics on the basis of their cost and especially considering concerns over the effects of indiscriminate use of on resistance."

Explore further: Booming mobile health app market needs more FDA oversight for consumer safety, confidence

add to favorites email to friend print save as pdf

Related Stories

Antibiotic use in infants linked to asthma

Jun 11, 2007

New research indicates that children who receive antibiotics before their first birthday are significantly more likely to develop asthma by age 7. The study, published in the June issue of CHEST, the peer-reviewed journal ...

Antibiotics found to increasingly fail

Apr 09, 2007

Pediatricians in the United States are increasingly finding that antibiotics are not always ideal for treating ear infections, a report says.

Antibiotic resistance lasts up to a year

May 18, 2010

Patients prescribed antibiotics in primary care may develop a resistance that lasts up to 12 months, according to research published in the British Medical Journal today.

Recommended for you

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

Jul 24, 2014

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

User comments : 0